Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Minerva Surgical

Explore full profile

Delivering next generation products for the treatment of abnormal uterine bleeding, a condition that affects almost 1 in 5 women

Cupertino, United StatesFounded 2008Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2026
Revenue $50–100M Latest reported FY
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding

About Minerva Surgical

Minerva Surgical specializes in providing a one-time treatment solution for women suffering from heavy menstrual bleeding. The company's core product, the Minerva Endometrial Ablation System, is designed to significantly reduce or eliminate heavy periods, with a reported 93% success rate in reducing menstrual flow to normal or less levels. The treatment is quick, averaging 3-4 minutes, and has high patient satisfaction, with 95% of patients willing to recommend the procedure to others.

Read full description

Minerva Surgical primarily serves women experiencing abnormal uterine bleeding (AUB) and collaborates closely with healthcare professionals, including gynecologists and obstetricians. The company operates within the medical device market, focusing on women's health. Its business model revolves around the sale and distribution of its proprietary endometrial ablation system to healthcare providers, who then offer the treatment to patients.

Revenue is generated through the direct sale of the Minerva Endometrial Ablation System to medical facilities and practitioners. The company also benefits from ongoing relationships with healthcare providers who recommend and perform the procedure.

Minerva Surgical's market presence is bolstered by FDA approval and endorsements from reputable medical organizations such as the American College of Obstetricians and Gynecologists and the American Association of Gynecologic Laparoscopists.

Source: Dealroom company data

At a glance

Founded
2008
Headquarters
Cupertino, United States
Listing
IPO 2021
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Latest news

Press, funding announcements and product moves mentioning Minerva Surgical.

See all news

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later1 investor entered at this stage

  • Armentum Partners
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.8%
🇮🇱 Israel1.2%
2 countries shown
Web traffic by country
3.6K monthly visits
across markets
🇺🇸 United States94.4%
🇮🇳 India5.6%
Top 2 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Minerva Surgical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Minerva Surgical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.